Filtered By:
Source: Metabolism - Clinical and Experimental
Drug: Cilostazol
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression
Conclusion: Taken together, our results demonstrated that cilostazol enhances LRP1 expression in liver by activating PPARĪ³ through the PPRE in the LRP1 promoter. Increased hepatic LRP1 may be essential for the reduction of circulating triglycerides brought about by cilostazol.
Source: Metabolism - Clinical and Experimental - October 21, 2013 Category: Biomedical Science Authors: Hyung Jun Kim, Jae Hoon Moon, Hyun Min Kim, Mi Ra Yun, Byung Hun Jeon, ByungWan Lee, Eun Seok Kang, Hyun Chul Lee, Bong Soo Cha Tags: Basic Science Source Type: research
